UBS Global Healthcare Conference - DAVITA INC

Financial Performance:

• U.S. dialysis volumes are growing this year, exceeding pre-pandemic baselines, with revenue per treatment (RPT) performing stronger than initially expected.
• International business growth is tracking at the expected long-term rate of 1% organic growth; International Kidney Care (IKC) is projected to contribute ~2% to operating income (OI) growth, outperforming the historical 1% norm.
• Operating income growth is being materially impacted by a headwind from IT and G&A spending, which has grown >20% annually for four years, specifically due to intentional investments in AI and core systems.
• Non-IT G&A components are being actively reduced to partially offset IT cost inflation.
• Free cash flow guidance remains $1.0–$1.25 billion; leverage is targeted at 3.4x, within the 3.0–3.5x range.
• Capital allocation strategy prioritizes growth investments (e.g., Alara, home health, Latin America) and maintaining liquidity, with excess free cash flow directed toward share buybacks.

Guidance and Future Outlook:

• Full-year 2027 Medicare ESRD rule effective increase is estimated at 1.5%–2.0%, significantly below the nominal 3.5% Q1 rate due to lagging DAPA add-on payment dynamics.
• Commercial mix headwinds related to the expiration of enhanced premium tax credits are projected to amount to a ~$70 million impact in 2027, following a ~$40 million headwind in the current year.
• Volume growth is expected to accelerate in 2027, targeting a return to >2% pre-pandemic levels, driven by a favorable calendar tailwind (approx. 25 bps) and recovery from 2026's clinic closure benefits.
• Expanded High-Dialysis (HD) dialyzers are rolling out nationwide in November, with financial impact and mortality benefits (based on CONVINCE study data) expected to materialize in the second half of 2028.
• IKC is positioned for sustained profitability, with new 10,000-member Humana contracts expected to incur initial costs before generating revenue in late 2027/early 2028.

Business Segments and Product Lines:

• U.S. Dialysis: Focusing on volume recovery, RPT optimization, and pharmaceutical cost mitigation via contracting and generic conversions.
• IKC: Demonstrating sustainable shared savings models and value delivery to payers; scaling operations despite the inherent complexity of CKD (non-ESRD) patient engagement.
• Innovation: Accelerated nationwide rollout of middle molecule clearance dialyzers; AI initiatives deployed to optimize drug protocols and operational efficiency.
• Strategic Partnerships: New commercial relationship with Humana targeting 10,000 CKD lives, though initial economics are expected to be negative in the short term.

Market and Competitive Landscape:

• The company views the proposed National Kidney Care Plan as having shared goals for innovation and quality but disagrees with the premise that LDOs are the primary problem or that reducing charitable premium assistance is a viable solution.
• DaVita argues that charitable premium assistance is critical for patient coverage retention and that its elimination would increase government costs without driving competition.
• Competitive dynamics involve a "vicious cycle" of mistreatments and hospitalizations, though the company attributes Q3 mistreatment spikes to broader national acute care admission trends rather than internal population health deterioration.
• The company differentiates itself through scale, enabling superior pharmaceutical price negotiation compared to independent providers.

Risks and Challenges:

• Reimbursement: The effective Medicare increase (1.5%–2.0%) lags behind nominal cost trends, creating a persistent funding gap, particularly in 2027.
• Commercial Mix: The erosion of commercial enrollment due to the expiration of premium tax credits poses a significant multi-year headwind to RPT.
• Cost Inflation: Intentional, high-growth IT spending (specifically AI) continues to pressure margins, though the growth rate is expected to decelerate in 2027.
• Regulatory/Political: Ongoing scrutiny regarding charitable premium assistance, FTC concerns, and potential legislative changes to the ESRD bundled payment system.
• Clinical Execution: Real-world efficacy of expanded HD dialyzers may differ from clinical trial results; mistreatment rates remain a clinical and operational risk.

Management Commentary and Tone:

• Management expresses high confidence in the long-term viability of the IKC segment and the sustainability of its shared savings model.
• Tone regarding U.S. dialysis is cautious but positive on volume, acknowledging current margin pressure from IT investment while framing it as a necessary foundation for future growth.
• Leadership is assertive in defending the company's role as part of the solution to healthcare cost issues, particularly regarding pharmaceutical stewardship.
• Confidence is high regarding the ability to mitigate revenue headwinds through pharmaceutical cost reductions and operational efficiencies.

Analyst Questions and Answers:

• Q: 2027 Volume Growth Drivers? A: Primarily calendar tailwinds (50 bps vs. prior year cycle), recovery from 2026 one-time clinic closure benefits, and the rollout of expanded HD technology.
• Q: Pharmaceutical Savings Mechanism? A: Opportunities include contracting, generic conversion, mix changes, dosing modifications, and AI-driven prescribing protocols; confidence stems from scale advantages in negotiating with pharma companies.
• Q: Expanded HD Financial Timeline? A: Revenue impact is expected in H2 2028, delayed by the 18-month clinical lag required for mortality benefits to manifest in real-world populations.
• Q: 2027 Medicare Rate Clarification? A: The 3.5% Q1 rate masks a lower full-year effective increase (1.5%–2.0%) due to variable DAPA add-on payments; the binder payment remains fixed at $1,285.
• Q: Charitable Premium Assistance Impact? A: Elimination would harm patients and increase government costs; the company views the program as a durable and necessary component of the ecosystem.

Other Key Points:

• Mistreatment rates in Q3 were attributed to a national surge in acute care admissions rather than a specific decline in patient health status.
• The "binder" payment in the ESRD bundle is considered a legacy revenue line that will disappear as a distinct component in the 2028 update.
• The company does not expect the 2027 ESRD rule changes to significantly alter commercial or Medicare Advantage contracting rates outside of Medicare Fee-for-Service dynamics.
• AI investment is currently a net cost with no immediate financial returns but is viewed as a long-term efficiency driver for revenue, bad debt collection, and cost control.